Changchun Jinsai Pharmaceutical Co., Ltd. (abbreviated as "Jinsai Pharmaceutical") is an innovation-driven full-industry-chain pharmaceutical enterprise dedicated to developing innovative drugs.
As a subsidiary of Changchun High-tech (state-owned, stock code 000661 SZ), Jinsai Pharmaceutical has a complete R&D, production, and sales industry chain, with annual revenue exceeding 10 billion RMB, nearly 10,000 employees, and a full-course protection chain covering screening, diagnosis, prevention, and treatment of major diseases, with over 30 core products launched.
Innovation is the development gene of Jinsai. To meet unmet clinical needs, the company continuously strengthens its layout in endocrine metabolism and women's and children's health, and prospectively lays out sub-fields such as oncology, rheumatology, immunology, dermatology, respiratory, nephrology, ophthalmology, and neurological diseases. With the goal of global first-in-class or best-in-class, relying on cutting-edge drug development technology platforms and multimodal technologies (large molecules/small molecules/small nucleic acids/cell and gene therapy), the company creates highly competitive drug molecules, accelerates translational research, seamlessly connects clinical trials, and has built a pipeline of 80+ high-potential and highly differentiated innovative drugs, covering major diseases in endocrine metabolism, oncology, immunology, and other fields.
In 2025, multiple core projects entered key clinical stages, and the rich pipeline reserve entered a harvest period, expected to continuously release new growth momentum and help the company open a new chapter of development.
At the same time, as a global leading enterprise in the growth hormone field, the company actively promotes industrial technology iteration and global market accessibility, expands growth hormone indications in adult and rare disease fields, and continues to lead the industry. It has also made breakthroughs in autoimmune diseases and oncology. On June 30, the Class 1 innovative drug for acute gouty arthritis - Fuxinkibaimab for injection (trade name: Jinbeixin) was approved for marketing, becoming the first interleukin-1β (IL-1β) monoclonal antibody in China. With long-acting anti-inflammatory effects and clear clinical benefits, it will lead a new era of gout treatment; in oncology, nanocrystalline megestrol acetate Meisiya explores a new field of cancer-related anorexia-cachexia, improving the quality of life of cancer patients and filling a huge market gap.
Promoting global accessibility of innovative drugs is the company's unremitting pursuit. The company has established strong commercialization capabilities covering multiple fields and large-scale autonomous production capacity benchmarking international quality standards. It looks forward to joining hands with more global innovation ecosystem partners to jointly promote the R&D and commercialization of innovative drugs and benefit patients worldwide.
What does Changchun Jinsai Pharmaceutical Co., Ltd. require? Who is Jinsai Pharmaceutical hiring? Jinsai Pharmaceutical recruitment: 销售类占比最多占58.4%，其次是医疗卫生/美容保健类占25.9%. What education can get in at Jinsai Pharmaceutical? 本科占比最多占52%，其次是大专占28.8%. High education required at Jinsai Pharmaceutical? 硕士占9.1%，博士占3%. Work experience required at Jinsai Pharmaceutical? 1-3年占比最多占31.3%，其次是不限占25.5%. Where are the job locations at Jinsai Pharmaceutical? 上海占比最多占22.1%，其次是长春占16.5%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
